Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 2-pyrimidinamine, 5-(8,9-dihydro-6,6-dimethyl-4-(4-morpholinyl)-6h-(1,4)oxazino(4,3-e)purin-2-yl)-
2. 5-(6,6-dimethyl-4-(4-morpholinyl)-8,9-dihydro-6h-(1,4)oxazino(4,3-e)purin-2-yl)-2-pyrimidinamine
1. 1382979-44-3
2. Paxalisib
3. Gdc0084
4. Paxalisib [usan]
5. 5-(6,6-dimethyl-4-morpholin-4-yl-8,9-dihydropurino[8,9-c][1,4]oxazin-2-yl)pyrimidin-2-amine
6. Chembl3813842
7. P5dkz70636
8. Gdc 0084
9. G02441729
10. 5-(6,6-dimethyl-4-morpholino-8,9-dihydro-6h-[1,4]oxazino[4,3-e]purin-2-yl)pyrimidin-2-amine
11. G-02441729
12. 2-pyrimidinamine, 5-(8,9-dihydro-6,6-dimethyl-4-(4-morpholinyl)-6h-(1,4)oxazino(4,3-e)purin-2-yl)-
13. 2-pyrimidinamine, 5-[8,9-dihydro-6,6-dimethyl-4-(4-morpholinyl)-6h-[1,4]oxazino[4,3-e]purin-2-yl]-
14. 5-[8,9-dihydro-6,6-dimethyl-4-(4-morpholinyl)-6h-[1,4]oxazino[4,3-e]purin-2-yl]-2-pyrimidinamine
15. 5-(6,6-dimethyl-4-morpholino-8,9-dihydro-6h-(1,4)oxazino(3,4-e)purin-2-yl)pyrimidin-2-amine
16. 5-(6,6-dimethyl-4-morpholino-8,9-dihydro-6h-[1,4]oxazino[3,4-e]purin-2-yl)pyrimidin-2-amine
17. Paxalisib [inn]
18. Paxalisib (usan/inn)
19. Unii-p5dkz70636
20. Schembl10239943
21. Gtpl10097
22. Bcp18386
23. Ex-a1019
24. Gdc-0084rg7666
25. Bdbm50177662
26. Mfcd30187522
27. Nsc792987
28. Rg7666
29. S8163
30. Who 11102
31. Akos030526470
32. Zinc149645112
33. Ccg-268430
34. Cs-5638
35. Db15186
36. Nsc-792987
37. Rg-7666
38. Sb19742
39. Compound 16 [pmid: 27096040]
40. Ac-31529
41. Bs-15481
42. Hy-19962
43. D11869
44. A909398
45. 5-(6,6-dimethyl-4-(4-morpholinyl)-8,9-dihydro-6h-(1,4)oxazino(4,3-e)purin-2-yl)-2-pyrimidinamine
| Molecular Weight | 382.4 g/mol |
|---|---|
| Molecular Formula | C18H22N8O2 |
| XLogP3 | -0.3 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 2 |
| Exact Mass | 382.18657197 g/mol |
| Monoisotopic Mass | 382.18657197 g/mol |
| Topological Polar Surface Area | 117 Ų |
| Heavy Atom Count | 28 |
| Formal Charge | 0 |
| Complexity | 552 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Enzyme Inhibitors
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Paxalisib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Paxalisib, including repackagers and relabelers. The FDA regulates Paxalisib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Paxalisib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Paxalisib supplier is an individual or a company that provides Paxalisib active pharmaceutical ingredient (API) or Paxalisib finished formulations upon request. The Paxalisib suppliers may include Paxalisib API manufacturers, exporters, distributors and traders.
Paxalisib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Paxalisib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Paxalisib GMP manufacturer or Paxalisib GMP API supplier for your needs.
A Paxalisib CoA (Certificate of Analysis) is a formal document that attests to Paxalisib's compliance with Paxalisib specifications and serves as a tool for batch-level quality control.
Paxalisib CoA mostly includes findings from lab analyses of a specific batch. For each Paxalisib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Paxalisib may be tested according to a variety of international standards, such as European Pharmacopoeia (Paxalisib EP), Paxalisib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Paxalisib USP).
LOOKING FOR A SUPPLIER?
